Shares of Terns Pharmaceuticals, Inc. (TERN) are surging 5.23% in pre-market trading on Tuesday, as the biopharmaceutical company receives a boost from positive analyst ratings and increased price targets. The stock's upward momentum comes amid growing optimism surrounding the company's potential in the healthcare sector.

Leading the charge, Mizuho Securities has reaffirmed its Buy rating on Terns Pharmaceuticals, setting an ambitious price target of $32. This vote of confidence from Mizuho analyst Graig Suvannavejh underscores the firm's bullish outlook on TERN's future prospects. Additionally, Barclays has raised its price target for Terns Pharmaceuticals to $28 from $27, while maintaining a Buy rating. Analyst Etzer Darout's decision to increase the target price signals growing confidence in the company's potential for growth and value creation.

The positive sentiment is further reinforced by a broader analyst report offering insights into healthcare companies, which includes Terns Pharmaceuticals alongside other sector players. This collective analyst attention and the consecutive positive ratings suggest that Wall Street is increasingly optimistic about Terns Pharmaceuticals' pipeline and market position, driving investor interest and contributing to the stock's pre-market rally.